AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Washington

SB5201

Concerning access to psychedelic substances.

Status

Pending

2026 Session

IntroducedJan 13, 2025 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Jesse Salomon (Democrat)
Type: Therapeutic Access
Substances: Psilocybin

Official text

Summary (from PoliPsy)

Concerning access to psychedelic substances.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: app.leg.wa.gov

Legislative history

January 12, 2026
By resolution, reintroduced and retained in present status.
February 13, 2025
Referred
February 11, 2025
In Committee
January 13, 2025
Referred
January 13, 2025
Introduced

Loading bill…